The farnesoid X receptor (FXR) is a member of the metabolic nuclear receptor superfamily that plays a critical regulatory role in cardiovascular physiology/pathology. However, the role of systemic FXR activation in the chronic phase in myocardial infarction (MI)-induced cardiac remodelling and dysfunction remains unclear. In this study, we aimed to elucidate the role of long-term FXR activation on post-MI cardiac remodelling and dysfunction. 
Introduction
Cardiovascular disease affects over 92 million adults in the United States (>1 in 3) , and is the leading cause of death in the developed world. 1 Cardiovascular diseases are rising as a cause of death and disability in China. 2 Myocardial infarction (MI) is the most common cause of heart failure (HF). Recently published data revealed that the over-all prevalence for MI in US adults > _20 years of age is 3.0%. MI causes myocyte death and the reduction in total number of functional cardiac myocytes ultimately results in poor cardiac pump function and HF. 3 Despite the significant advances that were achieved in HF therapies in recent decades, the mortality caused by HF remains extremely high. Therefore, identifying novel therapeutic strategies that are capable of blocking or reversing post-MI HF are greatly warranted. The farnesoid X receptor (FXR, NR1H4) is a member of the nuclear hormone receptor superfamily. FXR is expressed in several tissues, including the liver, intestines, adipose tissue, the vascular wall, pancreas, and kidneys. 4 FXR is activated by physiological concentrations of bile acids or synthetic FXR agonists including GW4064 and fexaramine. [5] [6] [7] FXR has been shown to play crucial roles in controlling the homeostasis of bile acids, lipoprotein and glucose metabolism, intestinal bacterial growth, platelet function, and in the response to hepatotoxins. [8] [9] [10] [11] Recent studies have shown that FXR is expressed in the cardiovascular system, including in vascular smooth muscle cells, vascular endothelial cells, and cardiomyocytes. [12] [13] [14] [15] Moreover, FXR plays an essential role in atherosclerosis, hypertension, and in myocardial ischemia/reperfusion (MI/R) injury. [15] [16] [17] [18] [19] Vascular smooth muscle cells undergo apoptosis when treated with a range of FXR ligands, in a manner that correlates with the ligands' ability to activate FXR. 12 During MI/R injury, myocardial FXR is up-regulated and promotes cardiomyocyte apoptosis. Pharmacological inhibition or genetic ablation of FXR reduced infarct size and improved cardiac function after MI/R. 15 In a recent study, it was reported that an increase of FXR expression in the acute phase of MI and genetic ablation of FXR resulted in reduced cardiac injury post-MI. 20 These studies strongly indicate that FXR up-regulation/over-activation directly contributes to apoptosis and cardiovascular injury. However, increasing evidence has demonstrated that FXR activation inhibits inflammatory responses in chronic cardiovascular diseases. During the development of atherosclerosis, activation of FXR demonstrated to inhibit vascular smooth muscle inflammatory responses. 21 Moreover, in a mouse model of atherosclerotic disease, loss of FXR function was associated with increased inflammatory gene expression. 18 In addition, in spontaneously hypertensive rats, chenodeoxycholic acid (CDCA), a natural ligand of FXR, reduced systolic blood pressure, improved vascular relaxation, and inhibited vasoconstriction. 22 In a rat model of monocrotaline-induced pulmonary hypertension, obeticholic acid induced FXR activation, and thereby attenuated right ventricular hypertrophy by blunting pathogenic inflammatory mechanisms and counteracting fibrosis. 23 In addition, ligand-bound FXR activates the transcription and release of several cytokines/hormones, including fibroblast growth factor (FGF)-15 (an orthologue of human FGF19), FGF21, adiponectin (APN), and leptin. [24] [25] [26] [27] These studies indicated a beneficial role of FXR activation in chronic cardiovascular diseases. However, whether long-term FXR activation improves post-MI cardiac remodelling and dysfunction is poorly understood. In this study, we investigated the role of long-term FXR activation on post-MI cardiac remodelling and dysfunction.
Methods

Animal models and drug administration
Animal experiments were approved by the Animal Care and Use Committee of the Fourth Military Medical University, and strictly followed the National Institutes of Health (NIH) guidelines on the Use of Laboratory Animals (NIH publication No. 85-23, revised 2011). In this study, male APN knockout (APN KO) mice (12-14 weeks of age) and age-matched wild-type (WT) mice were used. The generation, breeding, phenotypic characteristics, and genotyping approach of these mice were previously described in detail. 28 Adult male C57BL/6J mice were purchased from the Laboratory Animal Center of the Fourth Military Medical University. To establish a mouse model of MI, mice were anesthetized by inhalation of 1-2% isoflurane, and left anterior descending coronary artery ligation surgery was performed as described in our previous study. 29 At 1 week after MI surgery, mice were gavaged with GW4064 (8% DMSO and 16% castor oil in saline) or vehicle at a dose of 25 mg/kg body weight (Selleckchem). 30 Drugs were given once a day for seven consecutive weeks or until the animal died. At 8 weeks after MI surgery, mice were anesthetized by intraperitoneal injection with 0.04 mg/g body weight of pentobarbitol sodium, and sacrificed by cutting the carotid artery from which blood was collected. Hearts were perfused with cold phosphate buffered solution (PBS) and a portion of the left ventricle (LV) was either frozen in liquid nitrogen for biochemical analysis or fixed in 4% paraformaldehyde for histological analysis. White adipose tissue (WAT) was frozen in liquid nitrogen for biochemical analysis.
Myocardial gene delivery
Adeno-associated virus 9 (AAV9)-harbouring FXR (AAV9-FXR) and control virus (AAV9-con) were prepared and delivered as previously described with minor modifications. 31 Briefly, AAV9-expressing mouse full length FXR (FXR, NR1H4) was constructed by Hanbio Co, Ltd (Shanghai, China). Moreover, pHBAAV-CMV-2A-ZsGreen-Nr1h4 (AAV9-FXR) was constructed by cloning the target gene NR1H4 into the pHBAAV-CMV-2A-ZsGreen vector. After sequence confirmation, pHBAAV-CMV-2A-ZsGreen-Nr1h4 was cloned into the recombinant AAV9 frame vector. The AAV9 vector was then amplified in HEK293 cells and the viral titer was measured. AAV9-con (pHBAAV-CMV-2A-ZsGreen) was constructed and produced concomitantly. In brief, mice were anesthetized using 2% isoflurane. Next, a skin cut (1.2 cm) was made over the left chest, and a purse suture was made. After dissection of the pectoral muscles and exposure of the ribs, the heart was smoothly and gently 'popped out' through a small hole that was made at the 4th intercostal space. Each adenovirus was diluted to 2.5 Â 10 11 particles and 25 lL was directly injected into the LV free wall using a 30.5G Hamilton syringe (Hamilton Co, Reno, NV, USA). Intramyocardial injections were performed as follows: (i) starting from the apex and moving toward the base in the LV anterior wall; (ii) at the upper part of the LV anterior wall; and (iii) starting at the apex and moving toward the base in the LV posterior wall. Immediately after delivery of the gene, the heart was placed back into the intrathoracic space, followed by manual evacuation of pneumothoraxes, closure of muscle, and the skin suture. One week after injection, mice underwent MI surgery as described above.
Determination of cardiac function
To determine cardiac function, echocardiography was conducted as previously described. 32 In brief, after mice were anesthetized by inhalation of 1-2% isoflurane, transthoracic two-dimensional motion-mode echocardiography (VisualSonics) was performed. The LV end-systolic dimension (LVESD), LV end-diastolic dimension (LVEDD), and LV ejection fraction (LVEF) parameters were collected and analyzed using the Vevo770 software program (VisualSonics). 
Determination of cardiomyocyte apoptosis
Apoptosis of cardiomyocyte in heart sections was determined by TdTmediated dUTP nick-end labelling (TUNEL, Roche), which includes the entire MI area commonly referred to as peri-infarct area, as described in our previous study. 33 The TUNEL/DAPI double-positive nuclei were counted as apoptotic nuclei, and the TUNEL-positive/DAPI-negative nuclei were considered as false-positive apoptotic signals. Apoptosis of cultured cardiomyocyte was determined by TUNEL or annexin V-fluorescein isothiocyanate (FITC) kit (Beyotime) followed by flow cytometric analysis (BD Biosciences). 34 
Determination of infarct size and interstitial fibrosis
For histological analysis, a total of ten sections (7-10-mM thick) per heart were prepared. To evaluate infarct size and interstitial fibrosis in the noninfarct area (including border and remote zone) in post-MI hearts, sections underwent Masson's-trichrome staining. High-magnification light micrographs were obtained using a light microscopy (Nikon). Data involving infarct size, fibrosis area and total area in hearts were quantified by Image-Pro plus 6.0 software (Media Cybernetics). The percentage of interstitial fibrosis was calculated based on the ratio of fibrosis area and total area.
Determination of angiogenesis
Heart sections were deparaffinized and subjected to antigen retrieval in hot citric acid buffer. After cooling, slides were permeabilized with 0.2% Triton-100 for 15 min and were blocked with 1% BSA in PBS for 2 h, and incubated over-night at 4 C with anti-CD31 primary anti-body (#GB13063, Servicebio). CD31 were visualized with donkey anti-goat secondary antibody conjugated with CY3 (#GB21404, Servicebio). Nuclei were stained with 4 0 , 6-diamidino-2-phenylindole (DAPI, GB1012, Servicebio).
Micrographs of immunostains were acquired via Nikon Eclipse C1 Microscope and Nikon DS-U3 camera. Myocardial capillary density was quantified by Image-Pro plus 6.0 software (Media Cybernetics).
Determination of APN concentration in plasma and conditioned medium (CM)
APN levels in plasma and CM were determined using a mouse APN ELISA kit (Roche, USA) following the manufacturer's guidelines.
RNA preparation and real-time PCR analysis
Total RNA was extracted from frozen tissues or cultured cells by using the MiniBEST Universal RNA Extraction Kit (#9767, Takara). RNA was reversetranscribed into cDNA using the PrimeScript TM RT reagent Kit with gDNA Eraser (DRR047A, Takara). RT-PCR was performed in triplicate using a PCR detection kit (DRR081A, TaKaRa) and a CFX96 system (Bio-Rad). Primer sequences are presented in Supplementary material online, Table S1 .
Protein extraction and western blot analysis
Tissue lysates were collected in RIPA buffer (P0013B, Beyotime) in the presence of protease-and phosphatase-inhibitor cocktails (#5872, Cell Signaling Technology). Proteins were separated on SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). Next, membranes were incubated over-night at 4 C with anti-bodies directed against FXR Beijing TDY Biotechnology, TDY055C). After washing, blots were incubated at room temperature for 1 h with horseradish peroxidase (HRP)-conjugated goat anti-mouse or goat anti-rabbit secondary anti-bodies (1:2000, Cowin Biotechnology, CW0102S or CW0103S). Proteins were visualized using an enhanced chemiluminescence kit (Millipore). The film was scanned by ChemiDocXRS equipment (Bio-Rad Laboratory, Hercules, CA, USA), and densities of the bands were analyzed by Quantity One software (Bio-Rad).
Culturing of NRVMs and in vitro hypoxia and oxidative stress assays
Neonatal rat ventricular myocytes (NRVMs) were isolated by dissociating cardiomyocytes that were harvested from 1-to 2-day-old Sprague-Dawley rats after they were anesthetized by inhalation of 1-2% isoflurane as previously described. 35 After isolation, NRVMs were cultured in Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and penicillin-streptomycin. To induce hypoxia in vitro, NRVMs were incubated in DMEM without serum or other supplements and were placed in a hypoxia chamber (95% N 2 þ 5% CO 2 ) for 9 h. To block adiponectin's effects on NRVMs, a neutralizing adiponectin antibody (ab3455, Abcam) was utilized. To induce oxidative stress, NRVMs were treated with 200 lM of H 2 O 2 for 3 h.
Determination of O 2 -production in cardiomyocyte
After H 2 O 2 treatment for 3 h, O 2 -produced in NRVMs was measured by staining with Dihydroethidium (DHE). NRVMs were stained with 10 lM DHE for 30 min at 37 C. After washing twice in PBS, cells were analyzed by flow cytometry (BD Accuri C6).
2.12 3T3-L1 cell culture, differentiation, treatment, and preparation of CM Adipocyte 3T3-L1 cells were obtained from the American Type Culture Collection (ATCC) and grown in DMEM, containing 10% FBS. The medium was changed every 2 days. When confluent, differentiation of cells was induced by adding differentiation medium (5 lM methylisobutylxanthine, 0.25 lM dexamethasone, and 1 lg/mL insulin in DMEM, containing 10% FBS). Methylisobutylxanthine and dexamethasone were removed after 2-3 days; however, insulin (1 lg/mL) was added to the medium for an additional 2-3 days. Subsequently, differentiated 3T3-L1 adipocytes were treated with 5 lM of GW4064 or DMSO in DMEM medium. To induce oxidative stress, differentiated adipocytes were treated with 200 lM of H 2 O 2 .
36 After incubating for 24 h, the medium was discarded and cells were washed twice with PBS. For obtaining CM, adipocytes were incubated with DMEM without serum or additional supplements for 12 h. CM was then collected for future studies. 37 
Oil Red O staining
Cells were washed twice with PBS and fixed with 10% formalin for 60 min at room temperature. Next, cells were stained with filtered Oil Red O solution (working solution: 60% Oil Red O stock solution and 40% distilled water) for 2 h at room temperature. Cells were washed with PBS and visualized by light microscopy.
Statistical analyses
Data are presented as the mean ± SEM and were analyzed using GraphPad Prism 7 software (GraphPad Software, USA). Kaplan-Meier survival curves were analyzed by the Gehan-Breslow-Wilcoxon test. For the analysis of two groups, an unpaired Student's t-test was conducted. One-way ANOVA with a post-hoc analysis was performed when more than two groups were compared. For one group following the same animals over-time, one-way ANOVA with repeated measures, followed by Bonferroni post-hoc testing was performed. For multiple groups following the same animals over-time, Heart weight-to-body weight ratios and lung weight-to-body weight ratios were calculated (n = 6-8). (D) Expression of remodelling related genes (ANP and BNP) in myocardial tissue were determined by RT-PCR and normalized to b-actin expression (n = 6-8). (E) Plasma BNP was determined by ELISA (n = 6-8). (F) Cardiomyocyte apoptosis (white arrows) in the peri-infarct area was determined by TUNEL staining (n = 6). Data were analyzed by KruskalWallis, followed by a Dunnun post-hoc test. (G) Capillary density in the peri-infarct area was determined by CD31 immunofluorescence staining (n = 6). (H and I) Expression of inflammatory genes (TNF-a and IL-6) and mitochondrial biogenesis related genes (PGC-1a and Nrf1) in the peri-infarct area were determined by RT-PCR and normalized to b-actin expression (n = 6). *P < 0.05, **P < 0.01. Unless otherwise indicated, data were analyzed by one-way ANOVA, followed by a Bonferroni post-hoc test. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; TNF-a, tumor necrosis factor-a; IL-6, interleukin-6; PGC-1a, peroxisome proliferator-activated receptor-c coactivator-1a; Nrf1, nuclear respiratory factor 1.
FXR activation improves post-MI remodelling and dysfunction two-way ANOVA with repeated measures, followed by Bonferroni posthoc testing was performed. Kruskal-Wallis with a Dunnun post-hoc test was performed when one or more groups have values that are all 0. P < 0.05 was considered statistically significant.
Results
FXR agonist exerted protection against post-MI cardiac remodelling and dysfunction
Myocardial FXR expression was up-regulated in the acute phase of MI. 15, 20 In this study, FXR protein expression in peri-infarct heart tissue at various time points were evaluated in the chronic phase. As shown in Supplementary material online, Figure S1A , myocardial FXR protein was significantly decreased at 1 week after MI surgery when compared with sham-operated mice (P < 0.05), and the decreased FXR expression was maintained at 2, 4, and 8 weeks after MI surgery (P < 0.01). At 4 weeks after MI surgery, both cytosolic and nuclear FXR levels were reduced (see Supplementary material online, Figure S1B ). Moreover, during the chronic phase of MI, mRNA expression of a small heterodimer partner (SHP), a well-known FXR target, was down-regulated in heart tissue (see Supplementary material online, Figure S1C ). Intriguingly, as the natural ligands of FXR, no significant differences in total bile acids were observed between sham and MI mice (see Supplementary material online, Figure S1D ). Together, these results indicated that during the chronic phase of MI, myocardial FXR expression and transcriptional activity were inhibited.
To elucidate whether systemic FXR activation was detrimental or beneficial for post-MI cardiac injury, GW4064, a synthetic FXR agonist, was used to activate FXR. 38, 39 In brief, mice underwent MI or sham operation, and 1 week after surgery, both sham and MI mice were treated with GW4064 (25 mg/kg/d for 7 weeks by gavage) or vehicle. Compared with vehicle, 1 week of GW4064 treatment significantly increased mRNA levels of FXR and FXR target genes SHP, glucose-6-phosphatase catalytic subunit (G6Pase), and solute carrier family 51 alpha subunit (Osta) in the heart, adipose tissue, liver, and intestines ( Figure 1A and B and see Supplementary material online, Figure S2A ). Although GW4064 did not alter whole body insulin resistance nor fat mass (see Supplementary material online, Figure S2B -D), MI þ GW4064 mice showed a higher survival rate compared with MI þ vehicle-treated mice (85% vs. 65%; Figure 1C ). As shown in Figure 1D , GW4064 treatment significantly increased LVEF and decreased the left ventricular internal diameter at the end of systole (LVIDs) and diastole (LVIDd) at 4 weeks and 8 weeks after MI surgery (all P < 0.01 vs. MI þ vehicle). In shamoperated mice, GW4064 treatment did not alter these echocardiographic parameters (all P > 0.05, Figure 1D ). At 8 weeks' post-MI, Masson's trichrome staining was performed to evaluate infarct size and interstitial fibrosis. As shown in Figure 2A , longterm GW4064 treatment reduced MI size and fibrosis, although the differences were not statistically significant. Furthermore, GW4064 treatment reduced both heart weight-to-body weight (HW/BW) ratio and lung weight-to-body weight (LW/BW) ratio ( Figure 2B and C) . At the molecular level, GW4064 treatment decreased mRNA expression of myocardial atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), as well as plasma BNP levels ( Figure 2D and E) . To determine the mechanisms responsible for the anti-remodelling effect of GW4064, apoptosis, angiogenesis, inflammation, and mitochondrial biogenesis were respectively assessed by TUNEL staining, CD31 immunofluorescence staining, and real-time PCR at 8 weeks' post-MI. Compared with vehicle treatment, long-term treatment with GW4064 reduced the number of TUNEL-positive cells in peri-infarcted areas of heart tissue, although a statistically significant difference was not reached ( Figure 2F) . Administration of GW4064 also resulted in increased myocardial capillary density ( Figure 2G) , decreased TNF-a and IL-6 mRNA levels ( Figure  2H) , and increased PGC-1a and Nrf1 mRNA levels ( Figure 2I ) in peri-infarct area. Together, these results demonstrated that long-term systemic FXR activation during the chronic phase of MI increased angiogenesis and mitochondrial biogenesis, reduced cardiomyocyte loss and inflammation, thus exerted protective effects against cardiac dysfunction and remodelling.
Myocardial FXR over-expression failed to exert significant cardioprotection
Up-regulation/over-activation of myocardial FXR promotes apoptosis of cardiomyocytes in mouse models of acute ischemia/reperfusion. 15 However, we demonstrated that a systemic FXR agonist exerted protective effects against cardiac dysfunction and remodelling during the chronic phase of MI. These results may be explained, in part, by the protection of myocardial FXR during the chronic phase of MI. To test this possibility, myocardial FXR was over-expressed using intramyocardial injection of AAV9 harbouring FXR (AAV9-FXR). An AAV9-harbouring control gene (ZsGreen) served as a negative control (AAV9-con). As shown in Supplementary material online, Figure S3 , myocardial FXR, as well as FXR target genes SHP, G6Pase, and Osta in the heart, were significantly up-regulated at 2 weeks post-AAV9-FXR injection. To study the role of FXR over-expression during the chronic phase of MI, MI or sham operation was performed 1 week after AAV9 injection. As expected, AAV9-FXR significantly increased myocardial FXR expression and activity in both sham and MI hearts at 1 week after MI surgery (2 weeks after AAV9 injection, Figure 3A and B).
Moreover, unlike GW4064 treatment, cardiac-specific FXR over-expression did not increase survival of post-MI mice ( Figure 3C) . No significant differences in LVEF, LVIDs, or LVIDd were observed by echocardiographic studies between MI þ AAV9-FXR and MI þ AAV9-con mice ( Figure 3D ). Over-expression of myocardial FXR also had little effect on apoptosis, HW/BW, or LW/BW ( Figure 3E-G) . In addition, no significant differences were observed in mRNA expression of ANP or BNP between MI þ AAV9-FXR and MI þ AAV9-con mice ( Figure 3H) . Thus, these results indicated that over-expression of myocardial FXR during the chronic phase of MI did not directly affect post-MI heart function and remodelling.
GW4064 treatment increased adiponectin expression and secretion, which activated AMPK-PGC-1a signalling and inhibited cardiomyocyte apoptosis
On the basis of the above results, we hypothesized that FXR agonist improved post-MI heart remodelling and function independent of myocardial FXR expression/activity. To identify the potential molecule(s) that mediate the cardioprotective effects of GW4064, we focused our study on four cytokines/hormones that were previously reported as downstream molecules of FXR. These cardioprotective factors include FGF-15 (orthologue of human FGF19), FGF21, APN, and leptin. As shown in Figure 4A , GW4064 treatment significantly increased plasma levels of APN (P < 0.01) and slightly increased plasma levels of FGF21 (P > 0.05). GW4064 treatment did not increase levels of FGF15 and leptin. APN is Cardiomyocyte apoptosis (white arrows) in the peri-infarct area was determined by TUNEL staining (n = 4-6). Data were analyzed by Kruskal-Wallis, followed by a Dunnun post-hoc test. (F and G) Heart weight-to-body weight and lung weight-to-body weight ratios were calculated (n = 6-12). (H) Expression of remodelling-related genes ANP and BNP in myocardial tissue were determined by RT-PCR and normalized to expression of b-actin (n = 6-8). *P < 0.05, **P < 0.01. Unless otherwise indicated, data were analyzed by one-way ANOVA, followed by a Bonferroni post-hoc test. SHP, small heterodimer partner; LVEF, left ventricle ejection fraction; LVIDd, left ventricular internal diameter at the end of diastole; LVIDs, left ventricular internal diameter at the end of systole; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide.
FXR activation improves post-MI remodelling and dysfunction a well-recognized adipokine, which exerts cardioprotective effects against ischemic heart diseases. 28, 40 To investigate the effects of an FXR agonist on APN expression, we performed both in vivo and in vitro studies. APN is mainly secreted from WAT, therefore, we evaluated FXR and SHP levels in both anatomic-close epicardial and remote epididymal WAT derived from sham and MI-operated mice. 41 We found that compared with sham-operated mice, mice that underwent MI surgery demonstrated a rapid reduction of FXR protein expression and SHP mRNA expression in both epididymal ( Figure 4B and C) and epicardial (see Supplementary material online, Figure S4A and B) WAT at 3 days after MI. In addition, MI resulted in a reduction of plasma APN levels at 3 days after MI ( Figure 4D ). Treatment with GW4064 significantly increased FXR protein expression/activity in both epididymal and epicardial WAT ( Figure 4E and F, see Supplementary material online, Figure S4C and D) and plasma levels of APN at 3d and 28d after GW4064 treatment (i.e. 10d and 35d post-MI; Figure 4G ). More importantly, LVEF values were directly correlated with plasma APN levels collected from both MI þ vehicle and MI þ GW4064 groups at 8 weeks post-MI (r 2 = 0.363, Figure 4H ). In cultured adipocytes, GW4064 treatment significantly restored APN mRNA and protein expression, which were downregulated by H 2 O 2 ( Figure 4I-K) . Since 4-hydroxynonenal (4-HNE, an oxidation product) and BNP are accumulated in post-MI heart tissue and in the circulation, 42 the effects of 4-HNE and BNP on expression/activation of FXR in NRVMs and differentiated 3T3-L1 adipocytes were evaluated. We found that neither 4-HNE nor BNP significantly alter FXR expression and activity in cardiomyocytes/adipocytes (see Supplementary material online, Figure S4E and F), suggesting that 4-HNE and BNP accumulation do not contribute to FXR down-regulation in post-MI heart tissue and adipose tissue. In another study, it was recently found that cross-talk exists between epicardial adipose and the heart based upon the observation that APN expression in human epicardial adipose tissue is controlled by paracrine effects of oxidation products (O À 2 ) released from the heart. 41 However, in our in vitro studies, we found that GW4064 failed to alter O À 2 production in cardiomyocytes after H 2 O 2 stimuli (see Supplementary material online, Figure S4G ). Collectively, these results showed that GW4064 increased APN expression and secretion in WAT in a non-O À 2 -dependent manner. In a previous study, it was reported that in adipose tissue of FXR knock-out (FXR KO) mice, rosiglitazone treatment failed to increase APN transcription. 43 We evaluated the effects of GW4064 administration on APN mRNA expression in adipocytes with or without the PPAR-c inhibitor, T0070907. We found that T0070907 did not block GW4064-induced adiponectin expression in adipocytes (see Supplementary material online, Figure S4H ). Therefore, FXR may act down-stream of PPAR-c in controlling APN transcription. Adipocytes secrete numerous cardioprotective factors, including APN, and are considered a promising cell source for the treatment of MI. As reported, CM exerts anti-hypertrophic effects on cultured cardiomyocytes via an APN-dependent pathway. 37, 44 However, in adipose tissue, MI leads to a rapid decrease of APN expression/secretion, 28 which, in vitro, can be mimicked by H 2 O 2 treatment. 36 To understand whether GW4064-induced APN is sufficient for its cardioprotective effects, we divided cultured adipocytes into the following four treatment groups: control þ vehicle, control þ GW4064, H 2 O 2 þ vehicle, and H 2 O 2 þ GW4064. NRVMs were subjected to normoxia or hypoxia. The CM of the above 4 groups of cultured adipocytes were collected and utilized for culturing NRVMs ( Figure 5A) . Indeed, H 2 O 2 led to a significant reduction in APN secretion, which was largely restored by GW4064 ( Figure 5B) . Then, cardiomyocyte apoptosis and AMPK-PGC-1a signalling, an APN's down-stream signalling pathway, were evaluated. As shown in Figure 5C , 9 h of hypoxia dramatically increased apoptosis of NRVMs (P < 0.01 vs. normoxia). Compared with fresh media (FM), CM from the control þ vehicle group (Con-veh-CM) and control þ GW4064 group (Con-GW-CM) showed significant protection against hypoxia-induced apoptosis of NRVMs (both P < 0.01 vs. hypoxia þ Con-veh-FM). Moreover, CM from the H 2 O 2 þ vehicle group (HO-veh-CM) largely lost its capacity to reduce apoptosis of NRVMs (P < 0.05 vs. hypoxia þ Con-veh-CM). Interestingly, CM from H 2 O 2 þ GW4064 cells (HO-GW-CM) restored its capacity to reduce apoptosis of NRVMs (P < 0.05 vs. hypoxia þ HO-veh-CM). However, when pretreated with a neutralizing APN anti-body (NAA), HO-GW-CM lost its anti-apoptotic effects (P < 0.01). At the molecular level, Con-GW-CM did not alter AMPK phosphorylation or PGC-1a expression in NRVMs compared with Con-veh-CM (P > 0.05, Figure 5D ). However, HO-veh-CM significantly inhibited AMPK phosphorylation and PGC-1a expression (both P < 0.01 vs. Con-veh-CM). Importantly, HO-GW-CM largely restored AMPK-PGC-1a, which was attenuated by the NAA.
Taken together, these results demonstrated that an FXR agonist increased APN expression and secretion in WAT, which activated AMPK-PGC-1a signalling and thereby inhibited cardiomyocyte apoptosis.
Adiponectin deficiency attenuated the cardioprotective effects of GW4064
Heart tissue only secrets limited amounts of APN, 45 therefore systemic FXR activation may exert cardioprotective effects in a WAT-dependent APN secretion. To test this hypothesis, we used APN KO mice, which were subjected to either MI þ vehicle or MI þ GW4064. After 8 weeks of follow-up, APN KO-MI þ vehicle mice showed a lower survival rate compared with WT-MI þ vehicle mice (45% vs. 70%, Figure 6A ). In addition, APN KO-MI þ vehicle mice showed decreased LVEF and increased LVIDs and LVIDd at 8 weeks after MI (all P < 0.05 vs. WT-MI þ vehicle, Figure 6B ). Consistently, the indicators of cardiac remodelling (fibrosis, HW/BW, LW/BW, ANP, BNP) were significantly increased in APN KO-MI þ vehicle mice ( Figure 6C-F) . Unlike WT mice, APN KO mice failed to respond to GW4064 treatment. As shown in Figure 6B -F, long-term treatment with GW4064 did not have any protective effects against post-MI cardiac dysfunction and remodelling (all P > 0.05). At the cellular level, GW4064 failed to alter cardiomyocyte apoptosis and angiogenesis ( Figure 7A and B) . At the molecular level, TNF-a, IL-6, PGC-1a, and Nrf1 mRNA levels in peri-infarct area were not changed by GW4064 treatment ( Figure 7C and D) . GW4064 did not activate AMPK-PGC-1a signalling in heart tissue of APN KO mice ( Figure 7E) . Thus, these results demonstrated that APN deficiency completely attenuated the cardioprotective effects of long-term GW4064 treatment in post-MI cardiac injury.
Discussion
Previous studies have shown that expression of FXR was up-regulated in ischemic areas during MI/R. During this time frame, FXR activation led to apoptosis of cardiomyocytes by disrupting mitochondria. 15 In the present study, we investigated the role of systemic FXR activation on post-MI cardiac remodelling and dysfunction during the chronic phase of MI. We demonstrated that long-term, whole-body FXR activation exerted protective effects against cardiac dysfunction and remodelling. To eliminate the possibility that myocardial FXR activation during the chronic phase may protect the heart, we over-expressed myocardial FXR by intramyocardial injection of AAV9-FXR, which is an AAV9-harbouring FXR. We demonstrated that, although FXR expression was restored, AAV9-FXR was not able to improve post-MI heart function, indicating that an FXR agonist exerted cardioprotective effects independent of myocardial FXR expression/activity. It is of special interest to note that forced FXR expression was not detrimental for the post-MI heart, which may be explained by the fact that FXR was dramatically down-regulated in the chronic phase and that AAV9-FXR only restored FXR to physiological level. FXR is highly expressed in several tissues other than the heart, including liver, intestine, and adipose tissue. 4 Another possibility to explain the cardioprotection of whole-body FXR activation was based upon FXR Differentiated 3T3-L1 adipocytes were exposed to control or H 2 O 2 (200 lM) and were treated with GW4064 (5 l M) or vehicle. After 24 h, conditioned medium (CM) was collected. Neonatal rat ventricular myocytes (NRVMs) were exposed to normoxia or hypoxia, and treated with fresh media (FM) or CM collected from 3T3-L1 adipocytes for 12 h. (B) APN levels in conditioned medium of 3T3-L1 adipocytes were determined by ELISA (n = 6). (C) Apoptosis of NRVMs was determined by TUNEL staining (n = 4-6). (D) Expression of P-AMPK and PGC-1a from NRVMs was determined by western blot analysis (n = 4). *P < 0.05, **P < 0.01. Data were analyzed by one-way ANOVA, followed by a Bonferroni post-hoc test. NAA, neutralizing adiponectin anti-body; P-AMPK, phospho-AMPK; PGC-1a, peroxisome proliferator-activated receptor-c coactivator-1a.
. >10-fold. 26 CDCA, an endogenous FXR ligand enhanced the major antiinflammatory and insulin sensitizing adipokines (APN, leptin). 27 To identify potential molecule(s) that mediate the cardioprotective effects of GW4064, we focused on the above-mentioned 4 cytokines/hormones including FGF15, FGF21, APN, and leptin. Among them, APN was most significantly increased by GW4064 during MI. Interestingly, GW4064
treatment stimulated APN expression in adipocytes under H 2 O 2 stimulation but had little effect on APN expression under normal conditions. APN is an adipocytokine secreted from adipose tissue that circulates in plasma at relatively high levels and has metabolic-regulatory, anti-inflammatory and anti-apoptotic roles. 40, 47, 48 Several clinical observations have demonstrated that plasma APN levels are significantly reduced in Figure 7 (A) Cardiomyocyte apoptosis (white arrows) in peri-infarcted areas was determined by TUNEL staining (n = 4-6). (B) Capillary density in the peri-infarct area was determined by CD31 immunofluorescence staining (n = 6). (C, D) Expression of inflammatory genes (TNF-a and IL-6) and mitochondrial biogenesis related genes (PGC-1a and Nrf1) in the peri-infarct area were determined by RT-PCR and normalized to b-actin expression (n = 6). (E) Expression of P-AMPK and PGC-1a in myocardial tissue were determined by western blot analysis (n = 4-6). *P < 0.05, **P < 0.01. Data were analyzed by one-way ANOVA, followed by a Bonferroni post-hoc test. TNF-a, tumor necrosis factor-a; IL-6, interleukin-6; PGC-1a, peroxisome proliferator-activated receptor-c coactivator-1a; Nrf1, nuclear respiratory factor 1; P-AMPK, phospho-AMPK.
. in vitro studies to test whether GW4064 administration exerts cardioprotective effects in an APN-dependent manner. Our in vitro studies showed that GW4064 increased APN expression and secretion in differentiated 3T3-L1 adipocytes, which activated AMPK-PGC-1a signalling in cardiomyocytes and inhibited hypoxia-induced apoptosis. More importantly, our in vivo studies using APN KO mice showed that the beneficial effects of long-term GW4064 administration were completely abolished by APN deficiency, indicating APN as a key hormone in down-stream FXR activation. FXR is expressed in adipose tissue, however its role remains poorly understood. After MI, APN expression and secretion were dramatically decreased. 52 In our previous study, we reported that rosiglitazone, a peroxisome proliferator-activated receptor c (PPARc) ligand, exerted cardioprotective effects that depended on its stimulatory APN effects. 28 In the present study, we found that whole-body FXR activation also promoted APN expression and secretion in adipose tissue. Previous studies have shown that in adipose tissue of FXR KO mice, rosiglitazone treatment failed to increase APN transcription. 43 Other studies also revealed the stimulatory effects of FXR agonists on APN secretion. 26, 27 In another study, it was recently reported that oxidation products (such as O À 2 and 4-hydroxynonenal) released from the heart, trigger PPARc-mediated up-regulation of APN in human epicardial adipose tissue. 41 Our mechanistic studies showed that T0070907, a PPARc inhibitor, did not block were gavaged with an FXR agonist (GW4064). GW4064 entered adipocytes via circulation and was bound to FXR. FXR activation caused by GW4064 in adipocytes increased the expression and secretion of APN, which went to the ischemic heart and exerted anti-remodelling effects by multiple cellular mechanisms, which included increasing mitochondrial biogenesis and angiogenesis, and repressing fibrosis, hypertrophy, apoptosis, and inflammation. FXR, farnesoid X receptor; APN, adiponectin.
GW4064-induced APN expression in adipocytes (see Supplementary material online, Figure S4G ). Moreover, GW4064 increased APN expression and secretion in WAT in a non-O À 2 -dependent manner. Therefore, FXR may act down-stream of PPAR-c in controlling APN transcription, and more importantly, APN, but not myocardial FXR, mediated cardioprotective effects of whole-body FXR activation.
It was demonstrated that myocardial FXR is up-regulated during MI/R injury and that FXR activation promoted cardiomyocyte apoptosis. 15, 20 However, in the present study, in which administration was started after one week of MI and continued for 7 weeks, GW4064 treatment improved post-MI cardiac remodelling and function. Therefore, the results of the present study and the two previous studies seem to be paradoxical. We currently do not have a clear explanation for the differences observed. The possible reasons may be the different disease models used, the locations of detection, and the therapeutic time windows. Because the pathophysiological processes of MI/R and MI vary, the mechanisms and actions of FXR intervention can be greatly different. Further indepth studies to elucidate the potential of FXR as a therapeutic target, especially in view of its seemingly contradictory actions in MI/R and MI hearts, are warranted.
In summary, we were the first to provide evidence that long-term, whole-body FXR activation during the chronic phase of MI increased APN secretion from adipose tissue, which circulated in plasma and ameliorated post-MI cardiac dysfunction and remodelling ( Figure 8) . In this study, we identified FXR agonism as a potential therapeutic strategy in post-MI HF.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
